Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma

SIMPLE SUMMARY: Chimeric antigen receptor (CAR) T cell therapy represents a major advancement in cancer treatment. Recently, FDA approved CAR-T cells directed against the CD19 protein for treatment of leukemia and lymphoma. In spite of impressive clinical responses with CD19-CAR-T cells, some patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Golubovskaya, Vita, Zhou, Hua, Li, Feng, Valentine, Michael, Sun, Jinying, Berahovich, Robert, Xu, Shirley, Quintanilla, Milton, Ma, Man Cheong, Sienkiewicz, John, Huang, Yanwei, Wu, Lijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956426/
https://www.ncbi.nlm.nih.gov/pubmed/33652767
http://dx.doi.org/10.3390/cancers13050981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956426/
https://www.ncbi.nlm.nih.gov/pubmed/33652767
http://dx.doi.org/10.3390/cancers13050981

Ejemplares similares